| Date Filed | Type | Description |
| 08/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
SC 13G/A
| FMR LLC reports a 6% stake in P3 HEALTH PARTNERS INC |
| 06/08/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/08/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/17/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/17/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/25/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/14/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/31/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/31/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/31/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/10/2023 |
SC 13G/A
| FMR LLC reports a 17.4% stake in P3 HEALTH PARTNERS INC |
| 02/14/2023 |
SC 13G/A
| LMR Partners LLP reports a 5.6% stake in P3 Health Partners Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 23.7% stake in P3 HEALTH PARTNERS INC |
| 01/25/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/11/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023 Henderson, Nev., January 11, 2023 -- P3 Health Partners Inc . , a patient-centered and physician-led population health management company, is participating in J.P. Morgan’ s 41st Annual Healthcare Conference, being held in San Francisco, CA from January 9-12, 2023. In advance of the associated presentation, P3 is reaffirming full-year 2022 financial guidance and announcing financial guidance for the full-year 2023. · For the full-year 2022, P3 is reaffirming the revenue guidance range given on the third quarter earnings call of between $1.025 billion and $1.075 billion, representing a 61% to 69% increase over 2021. · The at-risk Medicare Advantage membership is still expected to be greater than 100..." |
|
| 12/28/2022 |
SC 13D/A
| Bacchus Amir reports a 7.9% stake in P3 Health Partners Inc. |
|